Год: 2020
Язык: Russian
Этот материал также есть на других языках: Английский Французский Испанский
Автор(ы): World Federation of Hemophilia
Формат: Видео
The development of inhibitory antibodies to therapeutic factor VIII (FVIII) in up to 40% of people with severe hemophilia A (HA) is the major complication in treatment/prevention of hemorrhages. The reasons some people with HA develop inhibitors while others do not, remain unclear.
In this session from the WFH 2020 Virtual Summit, Sebastien Lacroix-Desmazes, Kathleen Pratt and Valder Arruder summarize our understanding of anti-FVIII immune responses, the roles of T cells, both effector and regulatory, and generally discuss the interplay between FVIII and the immune system, both in the case of replacement therapy and in gene therapy.
Click on the icon below to access more on-demand Virtual Summit recordings.
This WFH webinar was originally presented in English.
The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.
The WFH does not promote any particular pharmaceutical product and any mention of any commercial brand in this presentation is strictly for educational purposes.
Also Available In: Japanese This patient handbook contains basic information about inhibitors, the most serious complication of hemophilia.
Also Available In: English, Spanish This is not an official WFH translation. This resource has been translated with permission by